Pfizer and Starna Therapeutics Enter $2.6 Billion Licensing Agreement for CAR-T Cell Therapies
Pfizer (PFE) has entered into an exclusive licensing agreement with China-based RNA medicines firm Starna Therapeutics to develop and commercialize chimeric antigen receptor T-cell (CAR-T) therapies. The deal is valued at up to $2.6 billion, structured through upfront payments, development milestones, and potential commercialization royalties. The partnership aims to leverage Starna's specialized technology to advance Pfizer's oncology pipeline. By integrating these advanced cell therapies, Pfizer seeks to strengthen its position in the competitive immunotherapy market and expand its capabilities in treating various forms of cancer.

Tickers: $PFE
Topics: Biotechnology CAR-T Therapy Drug Development Pharmaceuticals